Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single‐centre analysis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of the European Academy of Dermatology and Venereology

• Publication date

  2018-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jdv.14629PMID 29024038
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of metastatic melanoma: a multidisciplinary approach.

  2017cited by this paper
• Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy.

  2017cited by this paper
• Ipilimumab: from preclinical development to future clinical perspectives in melanoma.

  2017cited by this paper
• Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients

  2017cited by this paper
• Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

  2017cited by this paper
• BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma

  2017cited by this paper
• Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study

  2016cited by this paper
• Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

  2016cited by this paper
• Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.

  2016cited by this paper
• Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab

  2016cited by this paper
• The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma

  2016cited by this paper
• Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

  2016cited by this paper
• Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma.

  2016cited by this paper
• CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

  2015cited by this paper
• Effectiveness and Tolerability of Ipilimumab: Experiences From 198 Patients Included in a Named-Patient Program in Various Daily-Practice Settings and Multiple Institutions

  2014cited by this paper
• Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab

  2013cited by this paper
• Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival.

  2013cited by this paper
• Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients

  2013cited by this paper
• Serum 25‐hydroxyvitamin D serum levels in a large German cohort of patients with melanoma

  2013cited by this paper
• Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

  2012cited by this paper
• Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

  2012cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

  2010cited by this paper
• Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.

  2010cited by this paper
• Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

  2010cited by this paper
• Absolute count of T and B lymphocyte subsets is decreased in systemic sclerosis

  2010cited by this paper
• Lymphocyte Subpopulations and Interleukin Levels in High-Risk Melanoma Patients Treated With High-Dose Interferon A-2B

  2002cited by this paper

• Prognostic Potential of Baseline Eosinophils at the Initiation of Immune Checkpoint Inhibitor Treatment of Metastatic Melanoma: A Systematic Review and Meta-Analysis

  2025cites this paper
• Higher serum vitamin D concentration and supplementation were associated with improved survival outcomes and treatment response in cancer patients receiving immunotherapy: A systematic review and meta-analysis.

  2025cites this paper
• The “Jekyll Side” of the S100B Protein: Its Trophic Action in the Diet

  2025cites this paper
• Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

  2024cites this paper
• Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy

  2023cites this paper
• Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1

  2023cites this paper
• Vitamin D Status Is Associated With Immune Checkpoint Inhibitor Efficacy and Immune-related Adverse Event Severity in Lung Cancer Patients: A Prospective Cohort Study

  2023cites this paper
• Retrospective Analysis of Neutrophil-to-Lymphocyte Ratio in Patients with Melanoma Who Received Ipilimumab Monotherapy or Ipilimumab in Combination with Nivolumab in Japan.

  2023cites this paper
• The Future of Artificial Intelligence Applied to Immunotherapy Trials

  2022cites this paper
• The gut wall's potential as a partner for precision oncology in immune checkpoint treatment.

  2022cites this paper
• Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.

  2022cites this paper
• Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients

  2020cites this paper
• The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients

  2020cites this paper
• Markers That are Used for Allergic Diseases Can the Be Used in Preeclampsia?

  2020cites this paper
• Melanoma: prognostic factors and factors predictive of response to therapy.

  2019cites this paper
• CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy

  2018cites this paper
• CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders

  2018cites this paper
• The S100B story: from biomarker to active factor in neural injury

  2018cites this paper
• CSF-S 100 B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders

  2018cites this paper
• Enterocolitis due to immune checkpoint inhibitors: a systematic review

  2018cites this paper
• S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies

  2018cites this paper
• Ipilimumab more and more discussed: urgent need for predictive markers of response

  2018cites this paper